 |
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt |
|---|---|
| Trade Name | |
| Orphan Indication | Idiopathic pulmonary fibrosis |
| EU Market Approval | EU |
| EU Designation Date | 2016-07-14 00:00:00 |
| Sponsor | Vicore Pharma AB |
